Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus

Emily F N Yuki, Eduardo F Borba, Sandra G Pasoto, Luciana P Seguro, Michelle Lopes, Carla G S Saad, Ana Cristina Medeiros-Ribeiro, Clovis A Silva, Danieli C O de Andrade, Leonard de Vinci K Kupa, Lorena Betancourt, Isabela Bertoglio, Juliana Valim, Camilla Hoff, Francisco F C Formiga, Tatiana Pedrosa, Esper G Kallas, Nadia E Aikawa, Eloisa Bonfa, Emily F N Yuki, Eduardo F Borba, Sandra G Pasoto, Luciana P Seguro, Michelle Lopes, Carla G S Saad, Ana Cristina Medeiros-Ribeiro, Clovis A Silva, Danieli C O de Andrade, Leonard de Vinci K Kupa, Lorena Betancourt, Isabela Bertoglio, Juliana Valim, Camilla Hoff, Francisco F C Formiga, Tatiana Pedrosa, Esper G Kallas, Nadia E Aikawa, Eloisa Bonfa

Abstract

Objective: To date, the only study that has assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but the sample size precluded an accurate analysis of the effect of individual drugs. Therefore, we evaluated the immunogenicity of an inactivated SARS-CoV-2 vaccine (Sinovac-CoronaVac) and the influence of different medications in SLE. Safety was also assessed.

Methods: We conducted a prospective controlled study of 232 SARS-CoV-2-naive SLE patients and 58 SARS-CoV-2-naive controls who were vaccinated with 2 doses of Sinovac-CoronaVac with a 28-day interval (day 0/day 28 [D0/D28]). Immunogenicity analysis at D0/D28 and D69 included anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC) and neutralizing antibodies (NAb) positivity. The influence of individual drugs on immune response and safety was assessed.

Results: Patients and controls were well balanced for age (P = 0.771). At D69, SLE patients showed a moderate SC (70.2% versus 98.1%; P < 0.001) and moderate frequency of NAb positivity (61.5% versus 84.6%; P = 0.002), although both frequencies were lower than in controls. Factors associated with lower SC in univariate analysis at D69 were prednisone use (odds ratio [OR] 0.215 [95% confidence interval (95% CI) 0.108-0.427], P < 0.001) and mycophenolate mofetil (MMF) use (OR 0.201 [95% CI 0.107-0.378], P < 0.001), whereas hydroxychloroquine (HCQ) use led to a 2.5 increase in SC (P = 0.011). SLE patients who were receiving HCQ monotherapy had similar SC to controls at D69 (100% versus 98.1%; P = 1.000). In multivariate analysis, prednisone and MMF use were independently associated with lower SC (P < 0.001) and NAb positivity (P < 0.001). Safety analysis revealed no moderate/severe adverse events.

Conclusion: Sinovac-CoronaVac has a moderate immunogenicity in SARS-CoV-2-naive SLE patients with an excellent safety profile. We further demonstrate that HCQ may improve SC, whereas prednisone and MMF had a major deleterious effect in vaccine response, reinforcing the need to investigate the role of temporary MMF withdrawal or a vaccine-booster dose (ClinicalTrials.gov identifier: NCT04754698).

© 2021 American College of Rheumatology.

References

    1. Gamboa‐Cárdenas RV, Barzola‐Cerrón S, Toledo‐Neira D, Reátegui‐Sokolova C, Pimentel‐Quiroz V, Zevallos‐Miranda F, et al. Predictors of hospitalization for COVID‐19 in patients with autoimmune rheumatic diseases: results from a community cohort follow‐up. Clin Rheumatol 2021;30:1–10.
    1. Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP. Determinants of COVID‐19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 2020;39:2789–96.
    1. Brito‐Zerón P, Sisó‐Almirall A, Flores‐Chavez A, Retamozo S, Ramos‐Casals M. SARS‐CoV‐2 infection in patients with systemic autoimmune diseases. Clin Exp Rheumatol 2021;39:676–87.
    1. Faye AS, Lee KE, Laszkowska M, Kim J, Blackett JW, McKenney AS, et al. Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID‐19: a matched cohort study from New York City. J Rheumatol 2021;48:454–62.
    1. Sarmiento‐Monroy JC, Espinosa G, Londoño MC, Meira F, Caballol B, Llufriu S, et al. A multidisciplinary registry of patients with autoimmune and immune‐mediated diseases with symptomatic COVID‐19 from a single center. J Autoimmun 2021;117: 102580.
    1. Saadoun D, Vieira M, Vautier M, Baraliakos X, Andreica I, da Silva JA, et al. SARS‐CoV‐2 outbreak in immune‐mediated inflammatory diseases: the Euro‐COVIMID multicentre cross‐sectional study. Lancet Rheumatol 2021;3:e481–8.
    1. Gianfrancesco M, Hyrich KL, Al‐Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID‐19 in people with rheumatic disease: data from the COVID‐19 Global Rheumatology Alliance physician‐reported registry. Ann Rheum Dis 2020;79:859–66.
    1. Fernandez‐Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. Leveraging the United States Epicenter to provide insights on COVID‐19 in patients with systemic lupus erythematosus. Arthritis Rheumatol 2020;72:1971–80.
    1. Saad CG, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, et al. Immunogenicity and safety of the 2009 non‐adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:1068–73.
    1. Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology (Oxford) 2012;516:1061–9.
    1. Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS‐CoV‐2 vaccination responses in untreated, conventionally treated and anticytokine‐treated patients with immune‐mediated inflammatory diseases. Ann Rheum Dis 2021;80:1312–6.
    1. Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik‐Wang JM, et al. Antibody response to a single dose of SARS‐CoV‐2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021. Doi: 10.1136/annrheumdis-2021-220289. Epub ahead of print.
    1. Braun‐Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS‐CoV‐2. Ann Rheum Dis 2021;80:1317–21.
    1. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti‐SARS‐CoV‐2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021;80:1306–11.
    1. Ammitzbøll C, Bartels LE, Andersen JB, Vils SR, Mistegård CE, Johannsen AD, et al. Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis. ACR Open Rheumatol 2021;3:622–8.
    1. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330–8.
    1. Izmirly PM, Kim MY, Samanovic M, Fernandez‐Ruiz R, Ohana S, Deonaraine KK, et al. Evaluation of Immune Response and Disease Status in SLE Patients Following SARS‐CoV‐2 Vaccination. Arthritis Rheumatol 2021;74:284–94.
    1. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS‐CoV‐2 Vaccine in Chile. N Engl J Med 2021;385:875–84.
    1. Medeiros‐Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med 2021;27:1744–51.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.
    1. Petri M, Orbai A, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677–86.
    1. Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, et al. A new SARS‐CoV‐2 dual‐purpose serology test: highly accurate infection tracing and neutralizing antibody response detection. J Clin Microbiol 2021;59:e02438–20.
    1. World Health Organization . WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. 2021. URL: .
    1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Euro Surveill 2020;25:2000045.
    1. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
    1. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
    1. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS‐CoV‐2 vaccine in healthy adults aged 18‐59 years: a randomised, double‐blind, placebo‐controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181–92.
    1. D'Silva KM, Serling‐Boyd N, Hsu TY, Sparks JA, Wallace ZS. SARS‐CoV‐2 antibody response after COVID‐19 in patients with rheumatic disease. Ann Rheum Dis 2021. Doi: 10.1136/annrheumdis-2020-219808. Epub ahead of print.
    1. Saxena A, Guttmann A, Masson M, Kim MY, Haberman RH, Castillo R, et al. Evaluation of SARS‐CoV‐2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi‐racial and multi‐ethnic cohort. Lancet Rheumatol 2021;3:e585–94.
    1. Ebinger JE, Fert‐Bober J, Printsev I, Wu M, Sun N, Figueiredo JC, et al Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS‐CoV‐2. Nat Med 2021;27:981–4.
    1. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS‐CoV‐2 naïve and recovered individuals following mRNA vaccination. Sci Immunol 2021;6:eabi6950.
    1. Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, et al. One dose of SARS‐CoV‐2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID‐19. J Clin Invest 2021;131:e149154.
    1. Aikawa NE, Kupa LV, Pasoto SG, Medeiros‐Ribeiro AC, Yuki EF, Saad CG, et al. Dynamics of inactivated SARS‐CoV‐2 vaccine antibody response in SARS‐CoV‐2‐seropositive autoimmune rheumatic disease patients [preprint]. SSRN 2021. E‐pub ahead of print.
    1. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine‐induced humoral immunity. Semin Immunopathol 2019;41:239–49.
    1. Jabal AK, Ben‐Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID‐19 vaccine: real‐world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill 2021;26:2100096.
    1. Earle KA, Ambrosino DM, Fiore‐Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID‐19 vaccines. Vaccine 2021;39:4423–8.
    1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS‐CoV‐2 infection. Nat Med 2021;27:1205–11.
    1. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID‐19 vaccine strategies. Nat Rev Immunol 2020;20:615–32.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅